INTRODUCTION: Statins are drugs that inhibit HMG Co-A reductase and have been shown to enhance bone formation in vitro and in vivo in rodents. However, the statins currently used for cholesterol-lowering have been selected for their capacity to target the liver where their effects on cholesterol synthesis are mediated and they undergo first pass metabolism. When given in lipid-lowering doses, these agents do not likely reach sufficient blood concentrations to reliably cause substantial increases in bone formation in humans. Moreover, statins are inactivated by cytochrome P450 enzymes, resulting in even less peripheral distribution of the biologically active moieties beyond the liver. METHOD: To investigate whether an alternate method of administration might produce beneficial effects on bone formation, we administered lovastatin by dermal application to rats to circumvent the first-pass effects of the gut wall and liver. RESULTS: We found that the statin blood levels measured by HMG Co-A reductase activity were higher, maintained longer and less variable following transdermal application than those following oral administration. Also the increased circulating statin levels were associated with significantly enhanced biological effects on bone. After only 5 days of administration of transdermal lovastatin to rats, there was a 30-60% increase in trabecular bone volume, and 4 weeks later, we observed more than a 150% increase in bone formation rates. There was also a significant increase in serum osteocalcin, a marker of bone formation. We also found that lovastatin administered transdermally produces these profound effects at doses in the range of 1% of the oral dose, without any evidence of the hepatotoxicity or myotoxicity that can occur following oral statin administration. Several doses (0.01-5 mg kg(-1) day(-1)) and dosage schedules were examined, and collectively the data strongly suggest a powerful anabolic effect but with an unusually flat dose-response curve. CONCLUSION: These results show transdermal application of statins produces greater beneficial effects on bone formation than oral administration does.
INTRODUCTION: Statins are drugs that inhibit HMG Co-A reductase and have been shown to enhance bone formation in vitro and in vivo in rodents. However, the statins currently used for cholesterol-lowering have been selected for their capacity to target the liver where their effects on cholesterol synthesis are mediated and they undergo first pass metabolism. When given in lipid-lowering doses, these agents do not likely reach sufficient blood concentrations to reliably cause substantial increases in bone formation in humans. Moreover, statins are inactivated by cytochrome P450 enzymes, resulting in even less peripheral distribution of the biologically active moieties beyond the liver. METHOD: To investigate whether an alternate method of administration might produce beneficial effects on bone formation, we administered lovastatin by dermal application to rats to circumvent the first-pass effects of the gut wall and liver. RESULTS: We found that the statin blood levels measured by HMG Co-A reductase activity were higher, maintained longer and less variable following transdermal application than those following oral administration. Also the increased circulating statin levels were associated with significantly enhanced biological effects on bone. After only 5 days of administration of transdermal lovastatin to rats, there was a 30-60% increase in trabecular bone volume, and 4 weeks later, we observed more than a 150% increase in bone formation rates. There was also a significant increase in serum osteocalcin, a marker of bone formation. We also found that lovastatin administered transdermally produces these profound effects at doses in the range of 1% of the oral dose, without any evidence of the hepatotoxicity or myotoxicity that can occur following oral statin administration. Several doses (0.01-5 mg kg(-1) day(-1)) and dosage schedules were examined, and collectively the data strongly suggest a powerful anabolic effect but with an unusually flat dose-response curve. CONCLUSION: These results show transdermal application of statins produces greater beneficial effects on bone formation than oral administration does.
Authors: J I Germershausen; V M Hunt; R G Bostedor; P J Bailey; J D Karkas; A W Alberts Journal: Biochem Biophys Res Commun Date: 1989-02-15 Impact factor: 3.575
Authors: K A Chan; S E Andrade; M Boles; D S Buist; G A Chase; J G Donahue; M J Goodman; J H Gurwitz; A Z LaCroix; R Platt Journal: Lancet Date: 2000-06-24 Impact factor: 79.321
Authors: R A Halpin; E H Ulm; A E Till; P H Kari; K P Vyas; D B Hunninghake; D E Duggan Journal: Drug Metab Dispos Date: 1993 Nov-Dec Impact factor: 3.922
Authors: F Camacho-Alonso; C Martínez-Ortiz; L Plazas-Buendía; A M Mercado-Díaz; C Vilaplana-Vivo; J A Navarro; A J Buendía; J J Merino; Y Martínez-Beneyto Journal: Clin Oral Investig Date: 2020-01-11 Impact factor: 3.573
Authors: Zhenshan Jia; Yijia Zhang; Yen Hsun Chen; Anand Dusad; Hongjiang Yuan; Ke Ren; Fei Li; Edward V Fehringer; P Edward Purdue; Steven R Goldring; Aaron Daluiski; Dong Wang Journal: J Control Release Date: 2014-12-24 Impact factor: 9.776
Authors: Jessica A Cottrell; Francis M Vales; Deborah Schachter; Scott Wadsworth; Rama Gundlapalli; Rasesh Kapadia; J Patrick O'Connor Journal: J Biomed Biotechnol Date: 2010-06-16
Authors: Gloria E Gutierrez; James R Edwards; Ian R Garrett; Jeffry S Nyman; Brandon McCluskey; Gianni Rossini; Alda Flores; Daria B Neidre; Gregory R Mundy Journal: J Bone Miner Res Date: 2008-11 Impact factor: 6.741